Approval of Glucosparc (metformin)

The pharmaceutical Glucosparc prolonged release tablet 500mg, 750mg and 1000mg, has been approved for sale in Sweden by the Medical Products Agency.

Glucosparc is a prescription drug that is used to treat type 2 diabetes in adults where only exercise and diet are not enough to control blood sugar levels. Glucosparc may be used alone or combined with other drugs that lowers blood sugar.

Glucosparc contains metformin, a substance that increases the effect of the body's own insulin, which in turn is needed for the body's cells to be able to get energy from glucose, the sugar that is absorbed from food and circulated via blood vessels to the body's cells. Medicines containing metformin have been approved in Sweden since 1965, but Glucosparc may be the first to provide it in the form of a prolonged release tablet. Prolonged release tablets with metformin have long been available in Europe and globally, but in the Nordics only in Finland.

Prolonged release tablets such as Glucosparc dissolve gradually over a longer period, compared to regular tablets that dissolve and are absorbed rapidly by the body. For some patients, the rapid absorption may lead to adverse events and then a prolonged release tablet may be a better choice.

The product is expected to be launched in EQL Pharma's third financial quarter 2021/22.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.